What is HC Wainwright’s Estimate for VYGR FY2030 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – HC Wainwright issued their FY2030 EPS estimates for shares of Voyager Therapeutics in a report issued on Wednesday, February 4th. HC Wainwright analyst P. Trucchio anticipates that the company will earn ($0.83) per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

A number of other brokerages also recently commented on VYGR. Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Wedbush restated an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Voyager Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $13.75.

Voyager Therapeutics Stock Performance

Shares of VYGR opened at $3.68 on Friday. The business’s 50-day moving average is $4.04 and its two-hundred day moving average is $4.07. The company has a market capitalization of $204.61 million, a P/E ratio of -1.70 and a beta of 1.30. Voyager Therapeutics has a fifty-two week low of $2.64 and a fifty-two week high of $5.66.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Monday, November 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.06. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. The firm had revenue of $11.15 million during the quarter, compared to analysts’ expectations of $7.86 million.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ProShare Advisors LLC acquired a new position in Voyager Therapeutics during the fourth quarter worth $44,000. Privium Fund Management B.V. increased its stake in shares of Voyager Therapeutics by 111.1% during the fourth quarter. Privium Fund Management B.V. now owns 95,000 shares of the company’s stock worth $373,000 after purchasing an additional 50,000 shares in the last quarter. Palumbo Wealth Management LLC acquired a new position in shares of Voyager Therapeutics during the 4th quarter worth about $151,000. Allspring Global Investments Holdings LLC raised its position in shares of Voyager Therapeutics by 9.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 61,775 shares of the company’s stock worth $249,000 after purchasing an additional 5,422 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in Voyager Therapeutics in the 4th quarter valued at about $64,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.